X

Trial Profile

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Balstilimab (Primary) ; Neratinib (Primary) ; QBS 10072S (Primary) ; VBI 1901 (Primary) ; Temozolomide
Indications Glioblastoma; Gliosarcoma
Focus Therapeutic Use
Acronyms INSIGhT

Most Recent Events

03 Jul 2024 Planned number of patients changed from 250 to 460.
14 Nov 2023 According to VBI vaccine media release, the company expects to initiate VBI-1901 arm in combination with balstilimab by year end.
18 Sep 2023 Inaugural Results (n=237) published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com